PARP1 and neoplasm: Anti-tumor immunogenic effects of RBN-2397 can be enhanced in PARP2, 3, 12, and 1/2 KO CT26 tumors while anti-proliferation effects are enhanced in PARP1 and PARP3 KO NCI-H1373 cells, suggesting that combinatorial treatments of different PARP inhibitors may sensitize colon and lung tumors.